Skip to main content

Table 2 Characteristics of individual mCRC patients retrospectively analyzed in this study

From: Efficacy of regorafenib combined with PD-1 inhibitors in elderly patients with advanced metastatic colorectal cancer

 

Age- ranges (year)

Sex

ECOG PS

Primary tumor location

Sites of metastasis when on treatment

KRAS /NRAS /BRAF mutation status

MMR or MSI status

Response and duration on prior Rego (mo)

Combining regimen

No. of cycles

Response

Regorafenib initial daily dose(mg)

Regorafenib

final daily dose(mg)

1

61–65

F

1

Left

Liver

KRAS Mt

Unknown

PD (2)

Rego + Cam

3

SD

120

80

2

61–65

M

0

Right

Liver, lung

Wt

MSI-H

No Prior Rego

Rego + Sin

16

SD

80

40

3

66–70

M

1

Left

Lung,bone,lymph nodes, peritoneum

KRAS Mt

MSS

PD (2)

Rego + Pem

6

SD

80

80

4

61–65

M

1

Left

Liver, lung, lymph nodes, peritoneum

KRAS Mt

MSS

No Prior Rego

Rego + Sin

4

SD

80

80

5

71–75

M

1

Right

Liver, lung

KRAS Mt

MSS

No Prior Rego

Rego + Tori

9

SD

80

80

6

61–65

F

1

Left

Liver, lung, lymph nodes

Unknown

Unknown

No Prior Rego

Rego + Sin

2

PD

80

80

7

61–65

F

1

Left

Liver, lung

KRAS Mt

MSS

No Prior Rego

Rego + Sin

4

SD

80

80

8

61–65

F

0

Left

Lung

Wt

MSS

SD (1)

Rego + Cam

1

Unknown

120

80

9

71–75

M

0

Left

Liver

KRAS Mt

MSS

SD (6)

Rego + Sin

13

SD

80

160

10

66–70

M

1

Right

Lung, lymph nodes

KRAS Mt

MSS

No Prior Rego

Rego + Cam

4

PR

80

80

11

61–65

F

2

Right

Lymph nodes, peritoneum

Wt

Unknown

No Prior Rego

Rego + Tisle

1

Unknown

80

80

12

66–70

F

1

Right

Peritoneum

KRAS Mt

MSS

No Prior Rego

Rego + Nivo

3

SD

40

80

13

66–70

M

1

Right

Liver, lymph nodes

BRAF V600E Mt

MSS

SD (1)

Rego + Sin

13

SD

80

160

14

66–70

F

1

Left

Lung

KRAS Mt

MSS

No Prior Rego

Rego + Sin

2

PD

80

80

15

66–70

F

1

Left

Liver, lung,bone

KRAS Mt

MSS

No Prior Rego

Rego + Sin

3

SD

80

80

16

66–70

F

1

Left

Liver, lung,lymph nodes

KRAS Mt

MSS

No Prior Rego

Rego + Cam

2

SD

80

80

17

76–80

F

1

Left

Liver

KRAS Mt

Unknown

No Prior Rego

Rego + Tori

6

SD

80

80

18

66–70

F

1

Left

Liver

Unknown

MSS

SD (8)

Rego + Cam

13

SD

120

120

19

66–70

M

2

Right

Lung,bone,brain

KRAS Mt

MSS

No Prior Rego

Rego + Cam

1

Unknown

80

80

20

71–75

F

2

Left

Liver, lung,lymph nodes

KRAS Mt

MSS

No Prior Rego

Rego + Sin

2

PD

80

40

21

66–70

F

0

Left

Lung, lymph nodes

KRAS Mt

MSS

SD (2)

Rego + Sin

15

SD

80

80

22

66–70

F

1

Left

Liver, lung,lymph nodes

Wt

MSS

No Prior Rego

Rego + Nivo

2

PD

80

40

23

66–70

M

1

Right

Liver

Wt

MSS

PD (6)

Rego + Sin

6

SD

80

80

24

61–65

F

0

Left

Lung, lymph nodes

KRAS Mt

MSS

No Prior Rego

Rego + Sin

12

PR

120

160

  1. Cam camrelizumab, ECOG PS, Eastern Cooperative Oncology Group performance status, F female, M male, mo months Mt mutant, MSI-H microsatellite instability high, MSS microsatellite stability, Nivo nivolumab, Pem pembrolizumab, PD progressive disease, Rego regorafenib, PR partial response, SD stable disease, Sin sintilimab, Tisle tislelizumab, Tori toripalimab, Wt wild-type